AI-Powered Blood Test Detects Early Retinal Damage in Diabetes
Scientists have developed an AI-assisted prediction tool that can identify patients with type 2 diabetes at high risk of developing diabetic retinal neurodegeneration (DRN) before symptoms appear. Their findings were published today in the journal PLOS Medicine.
“Our study suggests that early retinal nerve damage in diabetes leaves measurable signals in the blood,” write the authors of the study, led by Wei Wang, MD, PhD, associate professor at the Guangdong Provincial Clinical Research Center for Ocular Diseases. “These findings suggest that a simple blood test analyzed with artificial intelligence may help identify people with diabetes who are at highest risk of early retinal nerve damage, well before visible damage appears on the retina.”
Type 2 diabetes affects more than half a billion people worldwide, carrying with it an increased risk of long-term complications including progressive neurodegeneration. Retinal nerves are among the earliest tissues to be damaged, which can eventually lead to severe visual impairment and vision loss. However, current diagnostic methods can only detect DRN once the retina has already suffered irreversible damage.
Wang and colleagues developed a machine learning algorithm called Pro-DRN using data from 1,218 participants in the Guangzhou Diabetic Eye Study, all of whom were diagnosed with type 2 diabetes but had not yet developed DRN at the time of enrollment. The AI model integrated proteomics data from blood samples with yearly retinal images collected over a six-year follow-up period.
This led to the identification of 71 proteins associated with the development of DRN. Among them, the proteins most consistently driving accurate predictions were ACTA2, COL6A3, and HSPG2, which are key structural components involved in maintaining the integrity of the nerve and muscle tissue in the eyes. These results were then validated in an independent cohort of 502 patients from UK Biobank, where the core effects and protein signals were reproduced.
Pro-DRN has been deployed as an interactive, web-based risk assessment tool that doctors can use to support early DRN screening and monitor patient evolution over time. Individuals identified as being at high risk of DRN could benefit from more frequent checkups and early interventions aimed at preventing or slowing down progressive neurodegeneration.
Because DRN is one of the first symptoms of nerve degeneration induced by diabetes, early detection could also signal the onset of nerve injury elsewhere in the body. Such damage can contribute to cognitive impairment, dementia, and peripheral neuropathy, which can cause loss of sensation and motor control in the hands, feet, and other extremities. A single eye test could therefore provide valuable insights into the overall health of the nervous system.
In addition, the proteins identified to be involved in DRN progression could be investigated as potential targets for the development of novel therapies. Furthermore, the AI-based tool could also prove valuable for the selection and stratification of participants in clinical trials evaluating neuroprotective strategies designed to prevent or delay nerve damage.
“Pro-DRN may help move diabetic eye care from detecting established damage toward earlier, molecularly informed risk stratification, so that closer monitoring and future neuroprotective interventions can be directed to the people most likely to benefit,” Wang and colleagues write.
The post AI-Powered Blood Test Detects Early Retinal Damage in Diabetes appeared first on Inside Precision Medicine.
Disease Detection Gets Boost from Keck’s New Brain Reference Map
Investigators at the USC Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI) at the Keck School of Medicine say they have created one of the largest reference models ever developed for the human brain, using diffusion MRI scans from more than 54,000 people to chart how the brain’s communication pathways develop, mature, and decline across the lifespan.
Published in Nature Communications, the study “Lifespan normative modeling of brain microstructure” provides the equivalent of growth charts for the brain’s white matter, the vast network of neural wiring that allows brain regions to communicate, according to the Keck team, which adds that the novel tool offers researchers a new way to detect subtle patterns linked to aging, Alzheimer’s disease, schizophrenia risk, and other neurological and psychiatric conditions.
“Just as pediatric growth charts help clinicians determine whether a child’s height or weight is developing as expected, these brain charts provide a reference for how the brain’s neural pathways typically change over the lifespan,” said Julio E. Villalón-Reina, MD, PhD, a postdoctoral researcher at the Stevens INI and the study’s first author. “That gives us a powerful new way to identify when an individual’s brain wiring falls outside the expected range.”
To study white matter, the team used diffusion MRI, an imaging method that tracks how water moves through brain tissue. Because water movement is shaped by microscopic features such as nerve fibers and myelin, diffusion MRI can reveal subtle changes in tissue organization not visible on standard brain scans.
After compiling diffusion MRI data from 54,583 individuals across 19 international datasets, the researchers built statistical growth and decline charts for the brain’s neural pathways.
The researchers focused on four widely used measures of white matter microstructure across 21 major brain regions. By modeling how these measures vary by age and sex, they generated lifespan curves and percentile ranges that show what is typical at different stages of life.
![Statistical charts compiled from a large population allow brain abnormalities to be detected in new individuals. [Stevens INI]](https://www.genengnews.com/wp-content/uploads/2026/06/Julio-Villalon-press-release-image-1920x1080-1-1024x576.jpg)
The results revealed that white matter follows distinct developmental and aging trajectories, with some measures reaching peak maturity in early adulthood and others later in midlife.
“Brain development and brain aging are not uniform processes,” continued Villalón-Reina. “The brain’s neural pathways mature on distinct timelines, and some are more vulnerable to decline than others. Our model reveals this structure by merging data on a truly global scale.”
The scientists also discovered evidence for a longstanding theory of brain aging, sometimes described as last in, first out. According to this theory, brain pathways that develop last in childhood and adolescence tend to be more susceptible to decline in older age. The researchers observed that white matter regions that mature later did indeed decline faster in old age, offering new insight linking brain development and aging.
To demonstrate the model’s practical value, the researchers applied it to clinical datasets from people with mild cognitive impairment, dementia, and 22q11.2 deletion syndrome, a genetic condition that increases risk of schizophrenia.
In each case, the model identified alterations in the brain’s circuitry that deviated from age-expected norms. Importantly, these deviations were not identical across individuals with the same diagnosis, highlighting the value of a person-specific approach.

“This monumental study took seven years to complete,” explained Paul M. Thompson, PhD, associate director of the Stevens INI and senior author of the study. “The vast scale of the data and the fine scale of the brain features assessed means we can now evaluate your neural pathways relative to other people of the same age, sex, and demographics. We can see how your brain differs from what we would expect for a person of your age and sex, giving us a tool to use in clinical trials of treatments for dozens of brain diseases.”
When applied to people with dementia and mild cognitive impairment, the model detected atypical white matter patterns in brain regions involved in memory and interregional communication. In people with 22q11.2 deletion syndrome, it identified deviations in multiple key neural pathways, helping researchers discover which brain systems develop differently.
The reference charts may also help researchers evaluate treatments by tracking whether a person’s white matter measures move closer to the expected range, or whether a treatment slows the shift away from healthy patterns over time. The charts will now be used to compare more than 30 brain diseases and conditions, offering a common framework for studying how different disorders emerge, progress, and respond to intervention.
The models are also a publicly available resource that can be extended as additional brain imaging data become available. The methods are now being used to study neurological, psychiatric, and neurodevelopmental disorders by providing a common reference standard for white matter microstructure across the lifespan.
“This study demonstrates the power of large-scale, international data sharing to create tools the entire research community can use,” pointed out Arthur W. Toga, PhD, director of the Stevens INI and provost professor at USC. “By establishing a lifespan framework for the brain’s communication pathways, this work opens new opportunities to detect subtle disease-related changes, compare conditions more rigorously, and move toward a more individualized understanding of brain health.”
The post Disease Detection Gets Boost from Keck’s New Brain Reference Map appeared first on GEN – Genetic Engineering and Biotechnology News.
Mature Intestinal Cells Revert to Stem-Like State to Sustain Colorectal Cancer
Researchers at the Stevens Institute of Technology have identified a mechanism that helps explain how colorectal cancer (CRC) develops, persists, and resists treatment. The research, published in the journal Cell Death & Disease, shows that mature intestinal cells that revert to a stem cell-like state can sustain tumor growth more effectively than mutated intestinal stem cells, a finding that could inform new drug development strategies focused on preventing CRC recurrence.
“Our study suggests that intestinal cancers can arise not just from damaged stem cells, but also from cells that revert into stem-like cancer cells,” said senior author Ansu Perekatt, PhD, an assistant professor of chemistry and chemical biology at Stevens Institute of Technology, “and they may contribute to why colorectal cancer can be diverse and resistant to treatment.”
Colorectal cancer is the second leading cause of cancer-related death worldwide. Cancer stem cells are known to play a role in tumor growth, metastasis, treatment resistance, and relapse. The new study focused on understanding how these cancer-driving stem cell populations emerge within the intestinal epithelium.
Two different models have been proposed for how colorectal cancer can develop. The most widely held belief is the “bottom-up” model which suggests that mutations in stem cells initiate tumor formation. By comparison, the “top-down” model suggests that mature epithelial cells acquire mutations, dedifferentiate into stem-like cells, and then drive tumor growth. Histological features observed in many human colorectal tumors have suggested a luminal, or top-down, origin.
Under normal conditions, Lgr5-positive stem cells reside in intestinal crypts and their role is to replenish the intestinal lining. As their progeny migrate from the crypts toward the villi in the intestine walls, they stop dividing and become specialized mature cells. However, previous research has shown that the intestinal epithelium is highly plastic and that differentiated cells can regain stem cell characteristics under certain conditions.
To better understand the biology of these pathways, the Stevens employed mouse model carrying Smad4 loss-of-function and β-catenin gain-of-function mutations, to mimic two common drivers of human colorectal cancer. They then tracked the behavior of both stem cells and differentiated epithelial cells.
The researchers also performed single-cell RNA sequencing to characterize the cellular populations that emerged during tumor initiation and progression allowing them to compare mutant stem cells residing in the crypts with dedifferentiation-derived stem-like cells arising in the villi.
The data showed that mutant Lgr5-positive stem cells in the crypts were at a competitive disadvantage. While they carried cancer-associated mutations, many were displaced and ultimately replaced by normal stem cells. At the same time, a subset of progenitor and epithelial cells underwent dedifferentiation and reacquired stem-cell properties making them capable of sustaining tumor growth.
“We don’t know why they change and why only a subset changes,” Perekatt said. “It’s very random, very sporadic. But when they change, they develop tumors.”
According to the study, dedifferentiating epithelial cells showed early expression of both CD44 and Lgr5, markers associated with stemness and tumor initiation. The Stevens team also found abnormal activation of Notch signaling in villus epithelial cells before the formation of tumor-associated crypt structures, suggesting that this pathway may contribute to the acquisition of stem-like properties.
The dedifferentiation-derived cells showed growth-factor independence, which allows them to proliferate without relying on the supportive niche environment normally required by stem cells. They also exhibited metabolic adaptations associated with tumor survival.
The study also found evidence of stem-cell heterogeneity within tumors. Single-cell analysis identified populations with distinct proliferative, signaling, and metabolic states. One mutant stem-cell cluster exhibited cancer-associated and embryonic stem cell-like gene signatures, while other clusters appeared more quiescent.
“Our findings suggest that metabolic adaptations and dedifferentiation-driven stem cell heterogeneity may enhance adaptability and confer a selective advantage driving top-down tumorigenesis,” the researchers wrote.
The findings have implications for current and future treatment strategies. Many therapies focus on eliminating actively growing cancer cells, but the study suggests that stem-like cells generated through dedifferentiation may remain capable of regenerating tumors after treatment. Targeting the mechanisms that enable mature epithelial cells to revert to a stem-like state could prove an effective method for preventing cancer recurrence.
“If you are only treating the cells that become cancerous without targeting the cells that acquired the de novo stemness, the cancer will likely come back,” Perekatt said. “So it’s really important to understand what causes this reversion to stemness, in order to develop new and effective therapies for colorectal cancers.”
Future research will focus on unanswered questions raised by the study, including the source of the Notch signals that trigger dedifferentiation, the transcriptional programs activated during this process, and the metabolic vulnerabilities of the resulting stem-like tumor cells.
The post Mature Intestinal Cells Revert to Stem-Like State to Sustain Colorectal Cancer appeared first on Inside Precision Medicine.
STAT+: Longevity startup NewLimit raises $435 million ahead of first clinical trial
Longevity startup NewLimit plans to launch its first clinical trial of a liver medicine after raising a staggering $435 million in new funding.
NewLimit announced its plans and Series C fundraising Tuesday. Founders Fund, the noted Silicon Valley venture capital firm co-founded by Peter Thiel, led the financing, which also included Thrive Capital, Lilly Ventures, and money from tech entrepreneurs Nat Friedman and Daniel Gross. The company is now valued at around $3.1 billion, according to co-founder and CEO Jacob Kimmel.
NewLimit was founded in 2021 by Coinbase CEO and co-founder Brian Armstrong, former GV partner and bioengineer Blake Byers, and Kimmel, a stem cell biologist. The South San Francisco-based startup has been moving rapidly, and grabbing investors’ attention. This is the third time in the past year that the company has announced it has raised money from investors — first, a $130 million Series B round in May 2025, followed by another $45 million in October.
New national action plan targets gaps at the intersection of mental health and criminal justice.
STAT+: Radiopharmaceutical shows promise in post-Pluvicto setting
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. Today, we’re looking at mixed reactions to a closely watched immunology trial and growing scrutiny of a type of telehealth business model.
The need-to-know this morning
- Vera Therapeutics and the FDA reached an agreement to allow Vera to accelerate the analysis of a confirmatory Phase 3 study involving atacicept, its treatment for the chronic kidney disease IgA nephropathy. The drug is already under review for accelerated approval, with a decision expected by July 7. The new FDA agreement will allow Vera to analyze its Phase 3 study, needed for full approval, in the third quarter, rather than wait for an additional year of data to accrue.
Abivax’s positive data weighed down by cancer concerns
Abivax said yesterday that its experimental treatment for ulcerative colitis showed significant efficacy in a closely watched maintenance trial.
Kinase Droplets Activate Growth Signals, Path for Cancer Therapy
A new study published in Cell Reports titled, “Kinase condensates enrich ATP and trigger autophosphorylation,” suggests that cellular phase separation, a mechanism that organizes biomolecules into dense, liquid-like condensates, may play a previously underappreciated role in regulating kinase activity. The findings suggest that aberrant condensate formation could contribute to oncogenic signaling while also offering new opportunities for drug targeting.
“Many biological molecules have this propensity to spontaneously separate,” said Lindsay Case, PhD, assistant professor of biology at Massachusetts Institute of Technology (MIT) and corresponding author of the study. “We were really interested in asking, if we have these kinases forming droplets, what is the consequence of that in the context of signaling?”
Phase separation occurs when proteins condense into highly concentrated liquid-like droplets within cells, analogous to oil droplets separating from vinegar. Although biomolecular condensates have emerged as important organizers of cellular processes, their impact on kinase signaling has remained incompletely understood.
The researchers examined three kinases: focal adhesion kinase (FAK), Mst2, and Abl. Across all three systems, condensate formation increased kinase activity by concentrating enzymes and substrates, thereby promoting phosphorylation reactions.
For FAK, the team found that elevated protein levels were sufficient to drive droplet formation and activate downstream growth signaling. The findings raise the possibility that FAK overexpression in tumors could promote constitutive signaling through condensate formation, potentially contributing to cancer progression and metastasis.
“It was surprising that just by condensing this protein into a droplet, you can actually turn on a signaling pathway that should be turned off,” said Case. “If FAK concentration is too high, you’re always getting these droplets and you’re always signaling, regardless of what the receptors that are supposed to be controlling this are doing.”
Mst2 and Abl also phase separated at high concentrations, which led to increased activity. For Mst2, phase separation is a strategy that healthy cells use to control the Hippo signaling pathway, which promotes cell growth and survival. Phase separation can also lead both enzymes to phosphorylate additional targets, and activate different signaling pathways.
“It’s not just that you’re getting faster phosphorylation, but in those cases, the patterns of what is actually getting phosphorylated were very different inside of the droplet compared to what might be happening in a non-droplet context,” Case says. “The kinase is able to phosphorylate amino acid residues beyond the set of canonical sites that have been described before.”
Mechanistically, the team found that kinase condensates selectively concentrate ATP, the phosphate donor required for kinase activity. Positively charged regions within kinases appear to recruit negatively charged ATP molecules to support phosphorylation.
Using machine-learning analysis, the investigators predicted that approximately 45% of the roughly 500 human kinases possess the molecular features needed to form similar condensates. The findings suggest that phase separation may represent a widespread regulatory mechanism that could influence both normal cellular signaling and disease-associated kinase activity.
In future work, Case hopes to explore designing drugs that could mimic ATP’s ability to be attracted into droplets within a cell, which could reduce side effects.
The post Kinase Droplets Activate Growth Signals, Path for Cancer Therapy appeared first on GEN – Genetic Engineering and Biotechnology News.

